A startup that wants to better understand the relationship our gut has to our brain just raised $66 million
Courtesy Kallyope
- Kallyope, a biotech startup working to map out the gut-brain axis, has raised $66 million.
- The series B round will help the company get some of its programs nearer to human clinical trials and continue research on the relationship between the gut and its microbes and the brain.
- The hope is that by investigating the gut-brain axis, researchers might be able to better treat certain metabolic conditions, like obesity, as well as neurologic conditions like Parkinson's disease.
A startup working to better understand the relationship our gut has with our brain has raised another $66 million.
New York-based Kallyope raised its series B round from new investors Two Sigma Ventures and Euclidean Capital. They were joined by Polaris Partners, Illumina Ventures, Lux Capital and others that had invested in Kallyope's $44 million series A round in 2015.
Kallyope is trying to figure out how exactly the brain interacts with the gut by mapping it out. By collecting sequencing information about cells in the gut, for example, Kallyope can better figure out how they're connected to neurons in the brain in a series of circuits. Understanding that relationship could lead to pills that could interact with the gut's signals and in turn pass that message along to the brain.
Over the past few years, even since launching the company, a lot has been learned about the gut-brain axis and the microbiome, the assortment of all the bugs that live in and on you that's an integral part of the gut, Kallyope CEO Nancy Thornberry told Business Insider.
That goes beyond conditions traditionally associated with the microbes in our gut, such as stomach and intestinal disorders. "There's now compelling evidence for a link between gut-brain and cognition, mood, and diseases such as autism, Parkinson's disease, and multiple sclerosis," Thornberry said.
While Kallyope hasn't given too many specifics about its drug programs, the company's initial focus will be in metabolic conditions, like obesity, as well as neurologic conditions like Parkinson's disease. The recent funding will be used toward building out Kallyope's gut-brain axis platform and getting one of Kallyope's programs near or into human clinical trials.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Catan adds climate change to the latest edition of the world-famous board game
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- Tired of blatant misinformation in the media? This video game can help you and your family fight fake news!
- JNK India IPO allotment – How to check allotment, GMP, listing date and more
- Indian Army unveils selfie point at Hombotingla Pass ahead of 25th anniversary of Kargil Vijay Diwas
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market